Japan Approves Eisai-Abbott Drug Humira For Two More Indications
This article was originally published in PharmAsia News
Executive Summary
Japan's drug regulator gave its approval of Eisai and Abbott Japan's Humira (adalimumab) for two additional indications, including Crohn's disease